Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 108 in Rheumatoid Arthritis
NCT00293826Phase 2Completed
- Sponsor
- Amgen
- Start
- Mar 2006
- Primary completion
- Nov 2007
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, randomised, double-blind trial of AMG 108 in rheumatoid arthritis (RA) (4 arms), sponsored by Amgen. Primary endpoint: American College of Rheumatology 20% Response at 24 weeks. Started Mar 2006; status: completed.
02
Drugs
AMG 108
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00293826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00293826.